Adaptimmune Therapeutics Plc Stock Price Prediction

ADAP Stock  USD 0.64  0.02  3.03%   
As of today, the RSI of Adaptimmune Therapeutics' share price is approaching 39. This suggests that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Adaptimmune Therapeutics, making its price go up or down.

Oversold Vs Overbought

39

 
Oversold
 
Overbought
The successful prediction of Adaptimmune Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Adaptimmune Therapeutics Plc, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Adaptimmune Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.11)
EPS Estimate Current Year
(0.15)
EPS Estimate Next Year
(0.49)
Wall Street Target Price
2.4333
EPS Estimate Current Quarter
(0.13)
Using Adaptimmune Therapeutics hype-based prediction, you can estimate the value of Adaptimmune Therapeutics Plc from the perspective of Adaptimmune Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Adaptimmune Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Adaptimmune because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Adaptimmune Therapeutics after-hype prediction price

    
  USD 0.66  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Adaptimmune Therapeutics Basic Forecasting Models to cross-verify your projections.
Intrinsic
Valuation
LowRealHigh
0.091.876.61
Details
Naive
Forecast
LowNextHigh
0.010.565.30
Details
9 Analysts
Consensus
LowTargetHigh
5.085.586.19
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.05-0.04-0.01
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Adaptimmune Therapeutics. Your research has to be compared to or analyzed against Adaptimmune Therapeutics' peers to derive any actionable benefits. When done correctly, Adaptimmune Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Adaptimmune Therapeutics.

Adaptimmune Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Adaptimmune Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Adaptimmune Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Adaptimmune Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Adaptimmune Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Adaptimmune Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Adaptimmune Therapeutics' historical news coverage. Adaptimmune Therapeutics' after-hype downside and upside margins for the prediction period are 0.03 and 5.40, respectively. We have considered Adaptimmune Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.64
0.66
After-hype Price
5.40
Upside
Adaptimmune Therapeutics is dangerous at this time. Analysis and calculation of next after-hype price of Adaptimmune Therapeutics is based on 3 months time horizon.

Adaptimmune Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Adaptimmune Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adaptimmune Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Adaptimmune Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  1.04 
4.57
  0.02 
  0.04 
10 Events / Month
12 Events / Month
In about 10 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.64
0.66
3.13 
22,850  
Notes

Adaptimmune Therapeutics Hype Timeline

Adaptimmune Therapeutics is presently traded for 0.64. The entity has historical hype elasticity of 0.02, and average elasticity to hype of competition of 0.04. Adaptimmune is forecasted to increase in value after the next headline, with the price projected to jump to 0.66 or above. The average volatility of media hype impact on the company the price is over 100%. The price gain on the next news is projected to be 3.13%, whereas the daily expected return is presently at -1.04%. The volatility of related hype on Adaptimmune Therapeutics is about 13057.14%, with the expected price after the next announcement by competition of 0.68. Adaptimmune Therapeutics Plc currently holds 25.23 M in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days.
Check out Adaptimmune Therapeutics Basic Forecasting Models to cross-verify your projections.

Adaptimmune Therapeutics Related Hype Analysis

Having access to credible news sources related to Adaptimmune Therapeutics' direct competition is more important than ever and may enhance your ability to predict Adaptimmune Therapeutics' future price movements. Getting to know how Adaptimmune Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Adaptimmune Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
STOKStoke Therapeutics 0.17 10 per month 0.00 (0.11) 4.68 (7.09) 21.35 
FIXXHomology Medicines(0.01)2 per month 3.52  0.02  5.77 (5.61) 19.43 
BDTXBlack Diamond Therapeutics 0.18 7 per month 0.00 (0.27) 5.81 (8.30) 26.00 
HARPHarpoon Therapeutics 0.00 0 per month 3.28  0.1  9.59 (6.25) 22.48 
MREOMereo BioPharma Group 0.02 7 per month 0.00 (0.10) 5.14 (5.79) 19.32 
PIRSPieris Pharmaceuticals 0.25 5 per month 0.00 (0.06) 3.23 (3.40) 13.07 
PDSBPDS Biotechnology Corp(0.15)10 per month 0.00 (0.17) 5.77 (6.76) 31.83 
LPTXLeap Therapeutics 0.05 3 per month 0.00 (0.03) 11.08 (7.03) 25.59 
AFMDAffimed NV(0.18)10 per month 0.00 (0.18) 6.39 (6.82) 21.12 
CRVSCorvus Pharmaceuticals 0.30 9 per month 3.13  0.22  9.38 (4.88) 23.11 
APTOAptose Biosciences 0.02 5 per month 0.00 (0.18) 5.41 (7.32) 16.03 
NKTXNkarta Inc 0.01 6 per month 0.00 (0.22) 6.50 (7.83) 24.02 
AGIOAgios Pharm(0.31)8 per month 2.43  0.08  5.24 (4.04) 15.93 
PLRXPliant Therapeutics 0.50 10 per month 0.00 (0.04) 5.37 (5.55) 24.35 
ACETAdicet Bio(0.02)9 per month 0.00 (0.18) 6.19 (6.54) 16.52 
INKTMink Therapeutics(0.01)6 per month 0.00 (0.14) 4.00 (3.85) 12.30 
IMGNImmunoGen 0.00 0 per month 1.44  0.17  8.32 (4.16) 141.41 
SGMOSangamo Therapeutics(0.19)8 per month 4.54  0.17  24.14 (7.53) 50.57 

Adaptimmune Therapeutics Additional Predictive Modules

Most predictive techniques to examine Adaptimmune price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Adaptimmune using various technical indicators. When you analyze Adaptimmune charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Adaptimmune Therapeutics Predictive Indicators

The successful prediction of Adaptimmune Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Adaptimmune Therapeutics Plc, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Adaptimmune Therapeutics based on analysis of Adaptimmune Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Adaptimmune Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Adaptimmune Therapeutics's related companies.
 2021 2022 2023 2024 (projected)
Payables Turnover13.6926.871.211.15
Days Of Inventory On Hand2.453.654.25.47

Story Coverage note for Adaptimmune Therapeutics

The number of cover stories for Adaptimmune Therapeutics depends on current market conditions and Adaptimmune Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Adaptimmune Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Adaptimmune Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Adaptimmune Therapeutics Short Properties

Adaptimmune Therapeutics' future price predictability will typically decrease when Adaptimmune Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Adaptimmune Therapeutics Plc often depends not only on the future outlook of the potential Adaptimmune Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Adaptimmune Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding201.1 M
Cash And Short Term Investments146.9 M

Additional Tools for Adaptimmune Stock Analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.